The Street loves a number like this; read the filing before you cheer. In its quarterly report for the period ended March 31, 2022, filed May 4, 2022, Moderna reported quarterly revenue of about $6.07 billion against research and development expense of roughly $554 million. On a single quarter’s arithmetic, that is staggering operating leverage.
Here is the fact that undercuts the easy reading: that revenue comes overwhelmingly from one product line. A company earning billions in a quarter from essentially a single source is not a diversified pharmaceutical business — it is a concentrated one having an exceptional run, and Moderna’s own filings repeatedly flag dependence on that concentration as a risk.
The contrarian’s discipline is to ask what happens to a number like this when the demand that produced it normalizes. The 10-Q records a quarter; it does not promise the next one. R&D at roughly $554 million for the quarter shows the company is reinvesting, but reinvestment is a multi-year bet whose payoff is, by definition, not yet on the income statement.
So the honest read of Moderna in spring 2022 is two truths at once: the current profitability is real and remarkable, and the durability of it is unproven and concentrated. The bull case is on the page in the revenue line; the bear case is on the page in the risk factors. Both are disclosed, not promised.
Every figure above is drawn from the company's primary SEC filing — surfaced through EdgarBeast, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.